Canada Diabetes Care Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Canada Diabetes Market is Segmented Into Drugs (by Category (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs), by Sub-Segment (Basal or Long-Acting, Bolus or Fast-Acting, Traditional Human Insulin Drugs, Insulin Biosimilars, GLP-1 Receptor Agonists, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors)) and Devices (Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-Monitoring Blood and Continuous Glucose Monitoring)). The Market Provides the Value (in USD) and Volume (in Units) for the Above-Mentioned Segments.

Canada Diabetes Care Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Canada Diabetes Care Drugs & Devices Industry Overview

Manufacturers have driven constant innovations to compete in the market. The major players, such as Abbott and Medtronic, have undergone many mergers, acquisitions, and partnerships to establish market dominance while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. The manufacturers of insulin delivery devices are spending a massive amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may help to enable insulin data to be shared between Novo Nordisk-connected insulin pens and digital health tools compatible with the FreeStyle Libre portfolio of products. Mega Blockbuster Lantus, manufactured by Sanofi, led the basal insulin field.

Canada Diabetes Care Drugs & Devices Market Leaders

  1. Roche

  2. Medtrionic

  3. Sanofi

  4. Novo Nordisk

  5. Omnipod

  6. *Disclaimer: Major Players sorted in no particular order
Canada Diabetes Care Drugs And Devices Market Concentration